A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
This study is testing a new experimental drug called ETX-19477 to see if it can safely and effectively treat advanced solid tumors. Researchers are looking for better ways to help patients when their cancer has continued to grow despite previous treatments.
This study is for adults with advanced cancers—such as breast, ovarian, prostate, or colorectal cancer—that have spread or cannot be removed by surgery. People with BRCA1 or BRCA2 gene changes are especially encouraged to apply, provided they are generally active and healthy enough for treatment.
Participants will receive the study drug and undergo regular check-ups to see how the medicine affects their body and their cancer. Doctors will monitor you closely using physical exams and imaging tests, like CT or MRI scans, to see how you are responding to the treatment.
The study is currently recruiting patients at medical centers in Phoenix, Arizona; New Haven, Connecticut; and Jacksonville, Florida. Please speak with your doctor to see if one of these locations is an option for you.
- 1The drug targets specific proteins in cancer cells to stop them from growing.
- 2Patients with BRCA2 mutations are a priority for enrollment.
- 3Participants must be able to perform their daily activities with minimal physical limitations.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.